# A Study of LY3143753 and LY3185643 in Healthy Participants

> **NCT02342314** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 68 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** LY3143753 (Part A)
- **DRUG:** LY3185643 (Part B)
- **DRUG:** Placebo (Part A and Part B)
- **DRUG:** rGlucagon (Part B)

## Key facts

- **NCT ID:** NCT02342314
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01
- **Primary completion:** 2016-09
- **Final completion:** 2016-09
- **Target enrollment:** 68 (ACTUAL)
- **Last updated:** 2019-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02342314

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02342314, "A Study of LY3143753 and LY3185643 in Healthy Participants". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT02342314. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*